ALLO - Allogene: Two End Of 2024 Data Readouts With Improved Allogeneic CAR-T Products
2024-06-12 13:09:17 ET
Summary
- Allogene Therapeutics, Inc. initiation of phase 2 ALPHA3 study, using cema-cel for the treatment of patients with 1st-line large B-cell lymphoma, expected in mid-2024 with two data analysis in 2026.
- Results from phase 2 ALPHA2 trial, using cema-cel for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia, expected by end of 2024.
- Results from phase 1 TRAVERSE trial, using ALLO-316 for the treatment of CD70 positive clear cell renal cell carcinoma patients, expected by the end of 2024.
- Company gained rights from Servier to expand use of cema-cel for r/r CLL and 1st-line LBCL in European and U.K. territories; New potential to tap into >$9.5 billion market opportunity if approval is achieved for these indications.
Allogene Therapeutics, Inc. ( ALLO ) has been able to advance a few CAR-T products in its pipeline. The reason why I believe that it is good to focus on this biotech next is because it is gearing up to report results from two early-stage studies, which could possibly boost shareholder value. The first candidate of which is known as cema-cel [formerly ALLO-501A] that is being advanced for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia [CLL]. The use of this candidate is being explored in the ongoing phase 1 ALPHA2 trial, and data from it is expected by the end of 2024....
Allogene: Two End Of 2024 Data Readouts With Improved Allogeneic CAR-T Products